Rossi Brings Decades of Leadership as Convergent Advances its Alpha-based Radioantibody for Prostate Cancer to Late-Stage Clinical DevelopmentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Convergent Therapeutics ...
Researchers have developed a new type of tumor-targeted alpha-particle therapy that has the potential to generically treat several kinds of cancer, with fewer negative side effects than currently ...
Alpha particle radioluminescence detection and imaging is an advanced optical technique that capitalises on the light emitted when alpha particles interact with air molecules. When alpha particles – ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to ...
Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results